1. Lippman A, Melnychuk R, Shimmin C, et al. Human papillomavirus, vaccines and
women's health: questions and cautions. CMAJ 2007; 177: 484-7. 2. Franco EL, Cuzick J …

Abstract This National Advisory Committee on Immunization statement concentrates on
specific elements of the analytic framework for human papillomavirus (HPV) immunization …

Background: A vaccine against human papillomavirus (HPV) types 6, 11, 16 and 18 is now
licensed for use in Canada and many other countries. We sought to estimate the number …

The development of human papillomavirus (HPV) vaccines and their potential for reducing
cervical cancer incidence and mortality are generally considered important steps to improve …

The debate surrounding the HPV vaccine1 might be characterized by 2 slogans:“Just do it”
versus “What's the hurry?” The HPV vaccination program's supporters see any potential …

Background Seventy percent of sexually active individuals will be infected with Human
Papillomavirus (HPV) during their lifetime. These infections are incriminated for almost all …

Epidemiological studies have provided ample evidence that sexual partners are the source
of practically all incidences of genital HPV infections. The fact that HPV is sexually …

Human papillomavirus (HPV) types 16 and 18 cause 70% of cervical cancers, and currently
two vaccines protecting against these types are available. In a previous paper, we estimated …

To be (most) effective, the very efficacious vaccines against oncogenic human
papillomaviruses have to be implemented into national vaccination programs. Inferences …

In June 2006, the Food and Drug Administration (FDA) approved the first human
papillomavirus (HPV) vaccine. The vaccine was subsequently recommended by the Centers …